【ChiCTR2600123728】The Development of a New Imaging Modality for Micro-TESE based on the Preliminary First Clinical Trial
ChiCTR2600123728
结束
/
/
/
2026-04-29
/
/
Male Infertility
The Development of a New Imaging Modality for Micro-TESE based on the Preliminary First Clinical Trial
The Need to Develop Micro-TESE in Male Infertility in Light of Current Literature: Investigation of the Clinical Effectiveness of a New Imaging Method
34899
/
The primary objective was to evaluate the diagnostic performance of a novel telecentric lens–based imaging system for identifying seminiferous tubules associated with sperm retrieval during micro-TESE in patients with NOA.
诊断试验诊断准确性
诊断试验新技术
None
/
This work was funded by a grant from the TUBITAK (The Scientific and Technological Research Council of Turkiye) (Protocol No.121S182). This fund was utilsed yo obtaind instruments (lens, camere etc.).
/
/
/
2020-01-05
2023-03-14
/
1. Male patients aged 18–40 years. 2. Diagnosis of non-obstructive azoospermia confirmed by at least two semen analyses. 3. Scheduled to undergo micro-TESE for infertility treatment. 4. Female partner eligible for intracytoplasmic sperm injection (ICSI). 5. Ability to understand the study procedures and willingness to provide written informed consent. 1. Male patients aged 18–40 years.2. Diagnosis of non-obstructive azoospermia confirmed by at least two semen analyses.3. Scheduled to undergo micro-TESE for infertility treatment.4. Female partner eligible for intracytoplasmic sperm injection (ICSI).5. Ability to understand the study procedures and willingness to provide written informed consent.；
请登录查看1. Obstructive azoospermia. 2. Known chromosomal abnormalities incompatible with sperm retrieval. 3. Prior testicular surgery significantly altering anatomy. 4. Inability or refusal to provide consent.；
请登录查看Department of Urology School of Medicine, Marmara University
34899
/
Department of Urology School of Medicine, Marmara University的其他临床试验
Department of Urology School of Medicine, Marmara University的其他临床试验
最新临床资讯
-
Nat Rev Clin Oncol｜AI赋能肿瘤临床试验：从流程优化到证据生成的全景透视
智药邦2026-08-12
-
康臣药业1类新药糖肾方“芪箭颗粒”获NMPA临床研究许可
康臣药业2026-08-12
-
璎黎药业2026-08-12
-
幂方健康基金2026-08-12
-
细胞与基因治疗领域2026-08-12
-
云南白药2026-08-12
-
细胞治疗前沿2026-08-12
-
广州达博生物制品有限公司2026-08-12
-
医药笔记2026-08-12
-
医药笔记2026-08-12
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 20 8
-
摩熵咨询 34 27
-
摩熵咨询 20 5
-
颁布机构：四川省经济和信息化厅、中共四川省委军民融合发展委员会办公室、四川省教育厅、四川省科学技术厅、四川省人力资源和社会保障厅、四川省卫生健康委员会、四川省医疗保障局、四川省中医药管理局、四川省药品监督管理局 2026-08-04
-
颁布机构：国家医保局 2026-07-31
-
颁布机构：国家药品审评中心（CDE） 2026-07-24
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-08-13
-
2026-08-13
-
2026-08-13
-
摩熵咨询 35 36
-
摩熵咨询 28 38
-
摩熵咨询 34 18
-
颁布机构：国家市场监督管理总局 2026-08-10
-
颁布机构：国家市场监督管理总局 2026-05-29
-
颁布机构：国家市场监督管理总局 2026-05-29